Amicus Therapeutics (NASDAQ:FOLD) Raised to Buy at StockNews.com

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other research firms have also weighed in on FOLD. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.63.

Amicus Therapeutics Trading Down 4.1 %

Shares of FOLD stock opened at $9.68 on Friday. The stock has a 50-day simple moving average of $11.00 and a 200 day simple moving average of $10.61. The stock has a market capitalization of $2.89 billion, a P/E ratio of -28.47 and a beta of 0.68. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 30,401 shares of company stock worth $352,038. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently modified their holdings of FOLD. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics in the third quarter worth $26,000. Hazlett Burt & Watson Inc. grew its stake in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. increased its position in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $55,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.